Ask AI
ProCE Banner Activity

When Good Isn’t Good Enough: Balancing the Augmentation Equation in MDD

Slideset

Choosing the next step after inadequate antidepressant response requires more than selecting another medication. These downloadable slides from Psychopharmacology Update 2026 examine the evidence guiding switching and augmentation in major depressive disorder, including newer comparative analyses of adjunctive atypical antipsychotics, strategies for persistent symptoms, and the balance between therapeutic benefit and adverse effects.

Released: November 18, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Target Audience

This activity is intended for physicians, physician associates, nurse practitioners, registered nurses, pharmacists, social workers, and psychologists engaged in the care of patients with psychiatric illness.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Assess optimal timing and clinical rationale for switching or augmenting treatment in patients with MDD

  • Evaluate the pharmacologic profiles, efficacy, and safety of approved adjunctive therapies for adults with MDD that improve residual symptoms, including anhedonia and cognitive impairment

  • Apply current guideline-based and evidence-based strategies to optimize dosing and titration of adjunctive therapies for adults with MDD who exhibit residual symptoms

Additional Disclosures

Generative artificial intelligence (AI) tools were used for revising or refining educational content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.